Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 26, 2017
Pharmacy Choice - Pharmaceutical News - Bayer receives FDA priority review for copanlisib to treat follicular lymphoma [Syrian Arab News Agency] - June 26, 2017

Pharmacy News Article

 5/19/17 - Bayer receives FDA priority review for copanlisib to treat follicular lymphoma [Syrian Arab News Agency]

German drug manufacturer Bayer has received priority review designation for the new drug application (NDA) for copanlisib from the US Food and Drug Administration (FDA).

The experimental drug is indicated to treat patients affected with relapsed or refractory follicular lymphoma (FL) and have received at least two prior therapies.

Bayer Pharmaceuticals America region head Carsten Brunn said: With this milestone, we are one step closer to making copanlisib available in the US to the community of doctors and patients facing a very difficult-to-treat disease.

We look forward to continuing to work with the FDA throughout the review process.

Copanlisibis is a pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against PI3K- and PI3K-.

The regulatory submission for copanlisib is based on Phase II, open-label, single arm CHRONOS-1 study data that assessed patients with relapsed or refractory indolent non-Hodgkin`s lymphoma (iNHL).

The study included 142 patients, 141 of which had iNHL.

"With this milestone, we are one step closer to making copanlisib available in the US to the community of doctors and patients facing a very difficult-to-treat disease."

CHRONOS-1 was designed to evaluate the efficacy and safety of copanlisib in the patients.

The primary endpoint of CHRONOS-1 is to assess the objective tumour response rate, while the secondary endpoints include the duration of response, overall survival, progression-free survival, quality of life and safety.

The collected data from this CHRONOS-1 trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held next month.

Non-Hodgkin`s lymphoma is regarded as the seventh most common cancer in the US and estimated to affect nearly 73,000 more people this year.



(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jun 27: Medication Adherence: To Take or Not to Take…That is the Problem
Last Chance
Jun 28: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Jun 29: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Jul 02: HIV Medications: Newer Drugs, Newer Guidelines
Jul 03: Management of Major Depressive Disorders
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415